PTTG1 and cancer: Our studies reveal the potential application of Verrucarin J as a novel therapeutic that targets both cancer cells and CSCs through the regulation of self-renewal signaling pathways (Notch1 and Wnt1), and oncogene “securin”, and hence reducing/eliminating the CSC population leading to reduction of drug resistance and recurrence of cancer (Figure 10).